Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) recovered 50% of its value since hitting low of $1.30. The recent move of -4.88% drop pushed the stock to close at $1.95 when trading ended on Nov. 2, 2017. At recent session, the prices were hovering between $1.86 and $2.145. This company shares are 207.69% off its target price of $6 and the current market capitalization stands at $40.85M. The recent change has given its price a 7.73% lead over SMA 50 and -59.38% deficit over its 52-week high. The stock witnessed 5.41% gains, 2.63% gains and -29.09% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TTNP’s volatility during a week at 12.05% and during a month it has been found around 13.07%.Titan Pharmaceuticals, Inc. (TTNP) Top Holders
Institutional investors currently hold around $6 million or 13.1% in TTNP stock. Look at its top three institutional owners. Vanguard Group Inc owns $1.36 million in Titan Pharmaceuticals, Inc., which represents roughly 3.33% of the company’s market cap and approximately 22.7% of the institutional ownership. Similar statistics are true for the second largest owner, Municipal Employees’ Retirement System Of Michigan, which owns 303,300 shares of the stock are valued at $622 thousand. The third largest holder is Renaissance Technologies Llc, which currently holds $572 thousand worth of this stock and that ownership represents nearly 1.4% of its market capitalization.
At the end of 06/30/2017 reporting period, 23 institutional holders increased their position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by some 1,024,009 shares, 32 decreased positions by 1,441,380 and 11 held positions by 314,419. That puts total institutional holdings at 2,779,808 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 878,588 shares while 19 institutional investors sold out their entire positions totaling 331,170 shares.Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Insider Trades
Multiple company employees have indulged in significant insider trading. Titan Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Akers Joseph A has acquired 13,000 shares of Titan Pharmaceuticals, Inc. (TTNP) in trading session dated Jul. 19, 2016. These shares are worth $63,050 and were traded at $4.85 each. The SEC filing shows that Bhonsle Sunil performed a purchase of 10,000 shares. The President and CEO added these shares by way of transaction on Jul. 18, 2016. The company’s shares were assimilated at $4.96 per share worth to an investment of some $49,600 on account of Bhonsle Sunil.
Director, Mcnab James R, purchased 20,000 common shares of Titan Pharmaceuticals, Inc. (TTNP) in the open market. In a transaction dated May. 31, 2016, the shares were bought at an average price of $7.03, giving away a sum of $140,600. After this purchase, 100,000 common shares of TTNP are directly owned by the insider, with total stake valued at $195,000.
In the transaction dated Feb. 22, 2016, the great number of shares acquired came courtesy the President and CEO; Bhonsle Sunil added a total of 11,763 shares at an average price of $3.56, amounting to approximately $41,876. The insider now directly owns 180,262 shares worth $351,511.Titan Pharmaceuticals, Inc. (TTNP) Analyst Guide
Not many analysts have released their opinion on Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.